Each September, Childhood Cancer Awareness Month (#CCAM) serves as a powerful reminder to honor children and families affected by pediatric cancer and to raise awareness for the urgent need for new treatment options.

At Plus Therapeutics (Nasdaq: PSTV), we are deeply committed to advancing care for children facing rare, aggressive brain and spinal cord tumors — cancers that often have a poor prognosis and limited treatment options.

About REYOBIQ™ (rhenium Re186 obisbemeda)

REYOBIQ™ is an investigational targeted radiotherapeutic being developed for the treatment of ependymoma and high-grade glioma (HGG) — rare, frequently fast-growing tumors in the brain and spinal cord that are particularly challenging to treat in children.

Delivered directly into the tumor site using advanced convection-enhanced delivery (CED) technology, REYOBIQ™ is designed to:

  • Deliver targeted radiation precisely to tumor cells

  • Minimize damage to healthy brain and spinal tissue

  • Improve treatment safety and effectiveness for pediatric patients

This therapy is currently being studied in the ReSPECT-PBC U.S. Phase 1 Clinical Trial, a first-in-human study evaluating the safety, dosimetry, and early efficacy of REYOBIQ™ in children with recurrent or progressive ependymoma and HGG.

Why This Matters for Childhood Cancer

  • Unmet Need: Children with ependymoma and HGG often face limited therapeutic options after standard surgery, radiation, and chemotherapy.

  • Innovation in Delivery: Convection-enhanced delivery (CED) bypasses the blood-brain barrier to directly target the tumor with radiation.

  • Hope for Families: REYOBIQ™ represents a potential new approach to improving outcomes for children with rare CNS tumors.

Learn More & Explore Trial Participation

If you are a caregiver, clinician, or patient advocate interested in learning more about the ReSPECT-PBC trial for REYOBIQ™, please visit our website and complete the interest form:

Learn More About ReSPECT-PBC & Trial Enrollment →

Supporting the Childhood Cancer Community

We proudly honor and support the efforts of organizations leading the fight against pediatric brain tumors, including:

  • American Childhood Cancer Organization (ACCO)

  • Children’s Brain Tumor Foundation

  • The Childhood Brain Tumor Foundation, Inc.

  • Children’s Brain Tumor Project Lab at Weill Cornell

  • Pediatric Brain Tumor Foundation

  • National Brain Tumor Society

  • American Brain Tumor Association

  • The EndBrainCancer Initiative (Chris Elliott Fund)

  • Al Musella Foundation

Together, we work toward a future where every child diagnosed with cancer has access to innovative treatments and better outcomes.

#ChildhoodCancerAwarenessMonth #CCAM #GoGold #ChildhoodCancer #PediatricCancer #ClinicalTrials #PlusTherapeutics #REYOBIQ #Radiotherapy #BrainTumors #Ependymoma #HighGradeGlioma #CancerResearch